α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.
Johannes LevinSimone BaiardiCorinne QuadaltiMarcello RossiAngela MammanaJonathan VögleinAlexander BernhardtRichard J PerrinMathias JuckerOliver PreischeAnna HofmannGünter U HöglingerNigel J CairnsErin E FranklinPatricio ChremCarlos CruchagaSarah B BermanJasmeer P ChhatwalAlisha DanielsGregory S DayNatalie S RyanAlison M GoateBrian A GordonEdward D HueyLaura IbanezCeleste M KarchJae-Hong LeeJorge Llibre-GuerraFrancisco LoperaColin L MastersJohn C MorrisJames M NobleAlan E RentonJee Hoon RohMatthew P FroschC Dirk KeeneCatriona McLeanRaquel Sanchez-VallePeter R SchofieldCharlene Supnet-BellChengjie XiongArmin GieseOskar HanssonRandall J BatemanEric McDadenull nullPiero ParchiPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
Cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) detects misfolded α-synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT-QuIC does not detect α-synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala-predominant variants. LBP develops late in the disease course in ADAD. CSF α-synuclein RT-QuIC has low sensitivity for focal, low-burden LBP.